ITEMS IN AFP WITH KEYWORD:
Oct 1, 2010 Issue
Bone Density Testing to Monitor Osteoporosis Therapy in Clinical Practice [Editorials: Controversies in Family Medicine]
The bottom line in caring for patients with osteoporosis is that monitoring for treatment effect is appropriate and desirable. A statistically significant BMD loss may lead to further evaluation and possibly a change in treatment. The strategy of monitoring therapy with BMD testing is supported by t...
Osteoporosis is an important and often overlooked problem in men. Although the lifetime risk of hip fracture is lower in men than in women, men are twice as likely to die after a hip fracture. Bone mineral density measurement with a T-score of -2.5 or less indicates osteoporosis. The American Colleg...
Feb 15, 2010 Issue
Combination Therapy for Postmenopausal Osteoporosis [FPIN's Clinical Inquiries]
There is insufficient evidence to recommend combination therapy for the routine management of postmenopausal osteoporosis.
The American College of Physicians (ACP) recently released guidelines on treatment of low bone mineral density (BMD) or osteoporosis to prevent fractures describes the available evidence on pharmacologic treatment in men and women.
Osteoporosis affects approximately 8 million women and 2 million men in the United States. The associated fractures are a common and preventable cause of morbidity and mortality in up to 50 percent of older women. The U.S. Preventive Services Task Force recommends using dual energy x-ray absorptiome...
Oct 1, 2008 Issue
ACP Guidelines on Screening for Osteoporosis in Men [Practice Guidelines]
Guidelines on screening for osteoporosis in men are available from the American College of Physicians (ACP). Although osteoporosis is commonly thought of as a disease that affects women, osteoporotic fractures also result in considerable morbidity and mortality in men.
Sep 1, 2008 Issue
Alendronate for Fracture Prevention in Postmenopause [Cochrane for Clinicians]
In postmenopausal women, a 10-mg daily dose of alendronate is effective for secondary (number needed to treat [NNT] = 16) and primary (NNT = 50) prevention of vertebral fractures. It is also effective for secondary prevention of nonvertebral fractures, including hip or wrist fractures (NNT = 100), b...
Zoledronic acid, in combination with calcium and vitamin D, will reduce the risk of vertebral fractures, and to a lesser extent, hip fractures in women with osteoporosis. It decreases subsequent fractures and mortality in high-risk patients who have had a hip fracture. Zoledronic acid may be most us...
Approximately one in six women will have a hip fracture during her lifetime, and approximately one in 35 of all women will die of complications from hip fracture.